Fannie Mae, Freddie Mac shares tumble after conservatorship comments
Investing.com -- Sumitomo Corp, a Japanese trading house, is entering the Asian cancer treatment market in partnership with U.S. nuclear fusion startup, Shine Technologies, according to Nikkei. The collaboration leverages Shine's expertise in radioisotopes to secure profits and establish a presence in the next-generation energy sector.
Shine Technologies, established in 2005, specializes in the development of fusion power generation technology using deuterium and tritium. This technology also enables the safe production of lutetium-177, a radioisotope that is effective in treating cancer.
In 2024, Shine inaugurated the largest lutetium-177 plant in North America, located in Wisconsin. The partnership with Sumitomo Corp extends Shine's reach into the Asian market, providing a new avenue for the application of its radioisotope technology in cancer treatment.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.